A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country

ConclusionThe present dosing regimen resulted in higher AUCs than targeted, necessitating a change in the dose regimen in future efficacy trials. No adverse effects that could be attributed to the use of 2-iminobiotin were observed.EudraCT number 2015-003063-12.

http://link.springer.com/10.1007/s40272-019-00373-3

Source: Pediatric Drugs - January 20, 2020 Category: Pediatrics Source Type: research